SCHEMBL20166414

SCHEMBL20166414

O=C(NC1CCS(O)(O)C1)c1ccc2c(-c3c(F)cccc3F)nn(-c3ccc(F)cc3)c2c1

nearest known ligand 0.84

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 20/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20166412 0.91 DGAT2 (1.00) DGAT2
SCHEMBL20167072 0.86 DGAT2 (0.85) DGAT2
SCHEMBL20166399 0.86 DGAT2 (0.85) DGAT2
SCHEMBL20166456 0.85 DGAT2 (0.84) DGAT2
SCHEMBL20166466 0.85 DGAT2 (0.85) DGAT2
SCHEMBL20167908 0.85 DGAT2 (0.61) DGAT2
SCHEMBL20166460 0.85 DGAT2 (0.86) DGAT2
SCHEMBL20167478 0.84 DGAT2 (0.86) DGAT2
SCHEMBL20166452 0.84 DGAT2 (0.85) DGAT2
SCHEMBL20166431 0.84 DGAT2 (0.87) DGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190330239-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2019-10-31 US claimed
EP-3541374-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 Merck Sharp & Dohme Corp. (US) 2019-09-25 EP claimed
WO-2018093696-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2018-05-24 WO claimed
US-20190330239-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330239-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 DGAT2, DGAT1, MOGAT2 DGAT2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.